IDV vehicle
36E79724D0019
NEW AWARD FOR EZETIMIBE TABLETS WITH MARLEX PHARMACEUTICALS. PERIOD OF PERFORMANCE IS APRIL 28, 2024 - APRIL 27, 2025 WITH FOUR ONE-YEAR OPTIONS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | NAC PHARMACEUTICALS (36E797) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $14.2M |
| Start date | Apr 28, 2024 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Aug 31, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 31, 2026 | P00004 | $0 | IMPLEMENTING EO 14398 DEI DISCRIMINATION |
| Feb 13, 2026 | P00003 | $0 | EXERCISE OF OPTION YEAR TWO FOR CONTRACT 36E79724D0019 FOR EZETIMIBE 10MG TABLETS WITH NO PRICE CHANGES. OPTION YEAR TWO IS EFFECTIVE 04/28/2026 TO 04/27/2027. |
| Mar 5, 2025 | P00002 | $0 | EXERCISE OF OPTION YEAR ONE FOR CONTRACT 36E79724D0019 FOR EZETIMIBE 10MG TABLETS WITH NO PRICE CHANGES. OPTION YEAR ONE IS EFFECTIVE 04/28/2025 TO 04/27/2026. |
| Feb 8, 2024 | P00001 | $0 | UPDATE TO COST RECOVERY FEE (CRF) AND SUBMISSION OF QUARTERLY SALES REPORTS |
| Jan 25, 2024 | 0 | $0 | NEW AWARD FOR EZETIMIBE TABLETS WITH MARLEX PHARMACEUTICALS. PERIOD OF PERFORMANCE IS APRIL 28, 2024 - APRIL 27, 2025 WITH FOUR ONE-YEAR OPTIONS |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.